# Open Orphan new contract win for Open Orphan’s Breda office & Covid update

- Link: https://www.directorstalkinterviews.com/open-orphan-new-contract-win-for-open-orphans-breda-office/4121009813
- Published: 2021-07-14T07:20:04+01:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist pharmaceutical services clinical research organisation(
CRO) and a world leader in vaccine and antiviral testing using human challenge clinical
trials, has announced a new contract win of c. €900,000 with an existing customer
for clinical trial management by our Breda, Netherlands office.

> **Cathal Friel, Executive Chairman of Open Orphan, said:  **_“This new contract
> win demonstrates the ongoing and continued success of our Breda office which continues
> to sign multiple contracts and only those close to £1 million and above are announced.
> Our Breda office is getting more and more integrated with our London business,
> and the entire Open Orphan group is excelling as the global leader in the testing
> of vaccines, anti-virals and other infectious disease therapeutics.” _

**Completion of CHIMagents acquisition**

Separately, and further to the Company’s announcement of 15 July 2020, Open Orphan
announces that it has completed its acquisition of CHIMagents Limited. CHIMagents
was established to assist in the design, manufacture and testing of challenge agents
for use in challenge studies. The CHIMagents team have been working alongside the
Open Orphan team since July 2020 supporting the design, manufacture and testing 
of both new challenge agents and the Company’s industry leading portfolio of existing
challenge study agents.

_**COVID-19 Human Challenge Programme  update**_

The company went on to announced that hVIVO, a subsidiary of Open Orphan plc, is
continuing to work with the UK Government to inoculate up to 20 further volunteers
as part of the world’s first COVID-19 characterisation study.

As part of the characterisation study, researchers aimed to identify a dose of COVID-
19 that causes a safe and reliable infection in unvaccinated COVID-19 naïve volunteers.
The UK Government has decided to expand the Human Challenge Programme to answer 
further questions that can help in the fight against COVID-19.

The study expansion will commence as soon as appropriate regulatory approvals and
clinical preparations are complete. The study is funded by the UK Government who
have commissioned Imperial College London to act as the clinical study sponsor. 
The study is conducted by hVIVO at the Royal Free Hospital, under the supervision
of our highly trained scientists and medics.

The virus being used in the characterisation study has been produced under hVIVO’s
supervision by a team at Great Ormond Street Hospital for Children NHS Foundation
Trust in London, with support from virologists at Imperial College London.

The data from this study is already providing valuable insight into the biology 
of the virus which causes COVID-19. This knowledge will improve the ability to manage
the virus and deliver a range of treatment options in the future. 

The revenue from the contract is expected to be recognised in the current financial
year.

**Cathal Friel, Executive Chairman of Open Orphan, said ****: **_“At Open Orphan
we are committed to helping the UK Government in partnership with two great institutions,
Imperial College London and the Royal Free Hospital, to discover effective treatments
for COVID-19. This study expansion further illustrates the effectiveness and importance
of this study.” _

**Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said ****: **_“We are 
delighted to announce this study expansion with the UK Government. This will enable
20_   _further_ _volunteers to participate in this next phase of the world’s first
study of its kind which will help scientists better understand and treat COVID-19._

“Open Orphan, through its subsidiary hVIVO, is proud to be working with the UK Government’s
Human Challenge Programme in this initiative to help control and minimise the spread
of the virus and we will look to provide updates on the study with further announcements
in due course.”

**Caroline Clarke, Royal Free London group chief executive, said **: _“We are excited
to enter this next phase of this study with our partners from hVIVO, Imperial College
London and the government’s Vaccine Taskforce. Ultimately, we hope this research
will give us more information about vaccines, as well as its impact on infection
rates, and enable us to provide better treatments in the future for patients with
COVID-19.”_

Share on:
